This site is intended for healthcare professionals

Reproxalap ophthalmic solution achieves statistical significance for primary and all secondary endpoints in phase III INVIGORATE clinical trial in allergic conjunctivitis- - Aldeyra Therapeutics.

Read time: 2 mins
Last updated:2nd May 2021
Published:2nd May 2021
Condition: Conjunctivitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest